Dr. Brentjens on Challenges of CAR-Modified T Cells

Renier J. Brentjens, MD, PhD
Published: Monday, Mar 31, 2014

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with CAR-modified T cells.

Getting CAR-modified T cells into the clinic was the first challenge, Brentjens says, but that is less of an obstacle now.

Now, physicians and researchers must cope with the side effects of CAR-modified T cells as well as how to address diseases where they do not work. A third challenges exists in expanding this therapy to other types of cancers. Brentjens believes investigators will focus on identifying target proteins or carbohydrates on the tumor cell surface for different tumor types. This will allow for the exploration of CAR-modified T cells in solid tumors and other types of hematologic malignancies.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with CAR-modified T cells.

Getting CAR-modified T cells into the clinic was the first challenge, Brentjens says, but that is less of an obstacle now.

Now, physicians and researchers must cope with the side effects of CAR-modified T cells as well as how to address diseases where they do not work. A third challenges exists in expanding this therapy to other types of cancers. Brentjens believes investigators will focus on identifying target proteins or carbohydrates on the tumor cell surface for different tumor types. This will allow for the exploration of CAR-modified T cells in solid tumors and other types of hematologic malignancies.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Publication Bottom Border
Border Publication
x